Proximity
Proximity, founded in 2020 and headquartered in San Francisco, is a biotechnology company specializing in next-generation induced proximity medicines.
Profile
Develops next-generation induced proximity medicines using a proprietary discovery platform.
Proximity, founded in 2020 and headquartered in San Francisco, is a biotechnology company specializing in next-generation induced proximity medicines. The company has developed the OmniTAC platform, a mechanism-agnostic proximity discovery engine that scans the 'effectome'—the set of effector proteins that modulate disease-causing proteins—to enable the development of highly efficacious therapeutics for previously untreatable targets. Proximity has raised over $20 million in funding, secured five 'Golden Ticket' awards from major pharmaceutical companies including AbbVie, Servier, Astellas, Ono, and Bristol-Myers Squibb, and received non-dilutive grants from ARPA-H and the NIH's National Cancer Institute.
The company has also announced a strategic multi-target collaboration with Daiichi Sankyo, applying its OmniTAC platform to several oncology programs. Proximity is advancing its own programs across oncology, cardiometabolic disease, neurodegeneration, and longevity. In May 2026, FreeMind Investments and Daewoong Pharmaceutical Co., Ltd. invested in Proximity, reflecting the company's strong scientific position and potential for future strategic collaborations.
Who buys this
- Pharmaceutical companies
- Biotechnology firms
- Research institutions
- Healthcare providers
- Investors in life sciences
Strengths and what to watch
Strengths
- Proprietary OmniTAC platform for unbiased proximity discovery
- Strategic collaborations with major pharmaceutical companies
- Non-dilutive funding from ARPA-H and NIH's National Cancer Institute
Watch for
- High dependency on strategic collaborations for revenue
- Potential challenges in scaling proprietary technology
- Regulatory hurdles in advancing new therapeutics
Recent moves
Key Information
- Founded
- 2020
- Headquarters
- San Francisco
Frequently Asked Questions
What is Proximity biotech?
Proximity is a San Francisco-based biotech firm founded in 2020, developing next-generation induced proximity medicines. Their proprietary OmniTAC platform identifies effector proteins that modulate disease-causing proteins, enabling treatments for previously untargetable conditions across oncology, cardiometabolic disease, neurodegeneration, and longevity.
How does Proximity's OmniTAC platform work?
The OmniTAC platform is a mechanism-agnostic discovery engine that scans the 'effectome'—the complete set of effector proteins influencing disease proteins. This systematic approach identifies novel therapeutic targets, enabling development of precision medicines for conditions lacking effective treatments.
Which pharmaceutical companies partner with Proximity?
Proximity has secured collaborations with Daiichi Sankyo and received 'Golden Ticket' awards from AbbVie, Servier, Astellas, Ono, and Bristol-Myers Squibb. These partnerships validate their technology and support multiple oncology programs through their OmniTAC platform.
What funding has Proximity received?
Proximity raised over $20 million, including investments from FreeMind and Daewoong Pharmaceutical in 2026. They've also secured non-dilutive grants from ARPA-H and NIH's National Cancer Institute, plus industry awards, supporting their research without equity dilution.
What diseases does Proximity target?
Proximity's programs address oncology, cardiometabolic diseases, neurodegeneration, and longevity. Their platform identifies targets across these areas, with active collaborations in oncology demonstrating immediate applications for their proximity medicine approach.
What challenges does Proximity face?
Key challenges include reliance on strategic partnerships for revenue, scaling their proprietary technology across multiple disease areas, and navigating complex regulatory pathways for novel therapeutic approaches. Their diversified collaboration model helps mitigate some of these risks.
Sources
- www.prnewswire.com — Investment by FreeMind Investments and Daewoong Pharmaceutical Co., Ltd.
- www.proximityhealth.com — Company overview and product details.
- www.sec.gov — Financial and operational details.
- www.sec.gov — Regulatory filings and financial data.